Trial Profile

A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GLPG 1205 (Primary) ; Nintedanib; Pirfenidone
Indications Idiopathic pulmonary fibrosis
Focus Proof of concept; Therapeutic Use
Acronyms PINTA
Sponsors Galapagos NV

Most Recent Events

03 Nov 2022 Results assessing efficacy, safety, and tolerability of GLPG1205 for treatment of idiopathic pulmonary fibrosis published in the European Respiratory Journal
30 Nov 2020 According to a Galapagos NV media release, full results from this study will be submitted to a future medical conference and peer-reviewed medical journals.
30 Nov 2020 Top-line results published in the Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com